Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclopentamine is a sympathomimetic alkylamine and vasoconstrictor that was formerly used as an over-the-counter nasal decongestant, primarily in Europe and Australia. It acts as a releasing agent for the catecholamines norepinephrine (noradrenaline), epinephrine (adrenaline), and dopamine, which underlies both its decongestant effects (via norepinephrine and epinephrine) and stimulant properties (via all three neurotransmitters). Structurally, it is related to methamphetamine but differs by having a cyclopentane ring instead of an aromatic phenyl ring. Cyclopentamine has been widely discontinued due to safety concerns, limited effectiveness, and the availability of safer alternatives such as propylhexedrine. It was also noted to be a very weak alpha-adrenergic receptor stimulant and weak beta-adrenergic receptor blocker[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclopentamine.